Trial Profile
A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of C21 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs C-21 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Vicore Pharma
- 02 Nov 2019 Status changed from not yet recruiting to discontinued.
- 11 Jul 2018 New trial record
- 03 Jul 2018 According to a Vicore Pharma media release, the company has received approval for this trial to be initiated in 2020.